Organisation paid for research Program year 2025 Source: CMS Open Payments

Trinity Universal Research Associates

Neither a doctor nor a teaching hospital

Research payments

$1,207,653

383 payments

Through program year 2025, Trinity Universal Research Associates is reported as receiving $1,207,653 in research payments, across 383 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$18,548	2
2024	Research	$191,501	83
2023	Research	$78,567	52
2022	Research	$26,662	1
2021	Research	$264,984	79
2020	Research	$375,902	105
2019	Research	$251,488	61

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $855,190 234 payments
GlaxoSmithKline, LLC. $148,513 40 payments
E.R. Squibb & Sons, L.L.C. $122,666 9 payments
Kiniksa Pharmaceuticals International, plc $65,093 53 payments
Kiniksa Pharmaceuticals, Ltd. $14,120 45 payments
Novartis Pharmaceuticals Corporation $2,000 1 payment
Pfizer Inc. $70 1 payment

Studies the money was for Research payments · program years 2019–2025

M16-560 $145,804 18 payments
A 24-Week, Phase 3, Multicentre, Randomised, Double-Blind, Efficacy An $124,211 25 payments
M13-549 $106,608 37 payments
M15-998 $97,278 19 payments
A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Subjects With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor $66,551 95 payments
Phase III PsA #2 (Wk52 driving submission) - A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis (PsA) who are Naive to Biologic $56,929 2 payments
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period $51,989 11 payments
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) $47,112 12 payments
M15-572 $42,799 13 payments
M13-542 $42,201 20 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.